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Abstract 
Aims. The aim of this study was to assess long‐term safety of intravenous cardiovascular agents—
vasodilators, inotropes and/or vasopressors—in acute heart failure (AHF).  
Methods and results .The European Society of Cardiology Heart Failure Long‐Term (ESC‐HF‐LT) registry 
was a prospective, observational registry conducted in 21 countries. Patients with unscheduled 
hospitalizations for AHF (n = 6926) were included: 1304 (18.8%) patients received a combination of 
intravenous (i.v.) vasodilators and diuretics, 833 (12%) patients received i.v. inotropes and/or vasopressors. 
Primary endpoint was long‐term all‐cause mortality. Main secondary endpoints were in‐hospital and post‐
discharge mortality. Adjusted hazard ratio (HR) showed no association between the use of i.v. vasodilator and 
diuretic and long‐term mortality [HR 0.784, 95% confidence interval (CI) 0.596–1.032] nor in‐hospital 
mortality (HR 1.049, 95% CI 0.592–1.857) in the matched cohort (n = 976 paired patients). By contrast, 
adjusted HR demonstrated a detrimental association between the use of i.v. inotrope and/or vasopressor and 
long‐term all‐cause mortality (HR 1.434, 95% CI 1.128–1.823), as well as in‐hospital mortality (HR 1.873, 
95% CI 1.151–3.048) in the matched cohort (n = 606 paired patients). No association was found between the 
use of i.v. inotropes and/or vasopressors and long‐term mortality in patients discharged alive (HR 1.078, 95% 
CI 0.769–1.512). A detrimental association with inotropes and/or vasopressors was seen in all geographic 
regions and, among catecholamines, dopamine was associated with the highest risk of death (HR 1.628, 95% 
CI 1.031–2.572 vs. no inotropes).  
Conclusions. Vasodilators did not demonstrate any association with long‐term clinical outcomes, while 
inotropes and/or vasopressors were associated with increased risk of all‐cause death, mostly related to excess 
of in‐hospital mortality in AHF.  
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Introduction 
Acute heart failure (AHF) represents a gradual or rapid change in heart failure (HF) signs and 
symptoms, requiring urgent medical therapies.1, 2 It is the most common cause of emergency 
department admission.3 The initial intravenous (i.v.) therapies of AHF have remained practically 
unchanged in the last decades. Most AHF patients are treated with diuretics and vasodilators, 
while others may also receive positive inotropes and/or vasopressors (mostly catecholamines). 
Several of these therapies have been shown to alleviate symptoms, though this did not translate in 
benefits on outcome.4 Furthermore, inappropriate use as well as increasing short‐term safety 
concerns have been reported regarding the use of inotropes and/or vasopressors in AHF.5, 6 Data, 
often on small samples, have suggested neutral (levosimendan in SURVIVE7) or even increased 
short‐term mortality with the use of catecholamines with positive inotropic effects (ALARM‐HF8 
or milrinone in OPTIME‐CHF9, 10). Data on long‐term safety of these agents, especially in 
hospital survivors, are scarce. Therefore, the aim of our study was to assess safety, namely long‐
term mortality, of i.v. cardiovascular agents, including vasodilators, inotropes, and/or vasopressors 
in AHF.  
Methods 
The European Society of Cardiology Heart Failure Long‐Term (ESC‐HF‐LT) registry was a 
prospective, observational registry that involved 211 cardiology centres from 21 European and 
Mediterranean countries. The study design and results have been previously described.11 Briefly, 
the ESC‐HF‐LT registry collected data on 12 440 patients on a one‐day‐per‐week basis between 
May 2011 and April 2013. Patients were followed up in accordance with the usual practice of the 
participating centres and had a mandatory follow‐up visit at 12 months to collect information on 
morbidity and mortality. Participation in the ESC‐HF‐LT registry had been approved by each local 
institutional review board in accordance with its country's legislation. All participants provided 
written informed consent.  
 
Patients with unscheduled hospitalizations for AHF were included in this study. Intravenous 
cardiovascular agents, namely vasodilators, inotropes and/or vasopressors, that were administered 
during the first 24 hours after admission, were assessed in the present analysis. We retrospectively 
analysed long‐term safety, especially mortality, of these agents. Primary endpoint was long‐term 
all‐cause mortality. Secondary endpoints were (i) in‐hospital mortality, (ii) post‐discharge all‐
cause mortality, (iii) post‐discharge all‐cause rehospitalization, and (iv) long‐term cardiovascular 
mortality.  
Statistical analysis 
Categorical variables are presented as counts and percentages, and quantitative variables as 
mean ± standard deviation or median and interquartile range (IQR), as appropriate.  
 
A propensity‐based matching approach was used to create a sample of patients receiving a 
specific treatment and a sample of control patients with similar characteristics, thus allowing 
comparisons of treatment with reduced bias. More specifically, two separate matched samples 
were created in AHF patients: one to compare i.v. vasodilators + i.v. diuretics vs. i.v. diuretics 
alone (see Supplementary material online, Figure S1), and one to assess i.v. inotropes and/or 
vasopressors vs. no i.v. inotropes and/or vasopressors treatment (see Supplementary material 
online, Figure S2).  
 
The propensity score is the probability that a patient with specific baseline characteristics 
would receive the treatment evaluated conditionally on individual characteristics. We estimated 
the propensity score using logistic regression, where the dependent variable was the treatment 
under study.  
  
The independent variables were patient and centre characteristics. All variables with a potential 
association with the treatment assignment and/or the outcome were used in these models, except if 
there were more than 10% missing values in the original database. More precisely, patient baseline 
characteristics used for propensity score development were age, gender, body mass index, primary 
diagnosis, clinical presentation, previous atrial fibrillation, obesity, diabetes, treatment of 
hypertension, peripheral vascular disease, chronic obstructive pulmonary disease, chronic kidney 
disease, liver dysfunction, depression, current malignant (cancer) disease, peripheral 
hypoperfusion/cold, peripheral oedema, pulmonary rales, New York Heart Association functional 
class, systolic blood pressure, diastolic blood pressure, heart rate, sodium, beta‐blockers and 
angiotensin‐converting enzyme inhibitors (ACEi) pre‐admission. Centre characteristics were 
country.  
 
Propensity‐based matching was used to create samples of patients treated by the therapy under 
study and not treated who were similar in terms of propensity score, i.e. in terms of probability of 
receiving the therapy. Unmatched observations were discarded, thus leading to possibly non‐
representative samples of the original database.  
 
A 1:1 matching optimal algorithm without replacement was used, where all treated patients 
were matched to the closest control within an appropriate range. The success of the propensity 
score matching was assessed by checking standardized differences between the groups before and 
after matching, expressed as a percentage. Balancing was considered as successful, if the 
standardized differences were less than 10% for variables used for propensity score development.  
 
The main endpoint of the study was long‐term all‐cause mortality. In addition, the secondary 
endpoints were all‐cause in‐hospital mortality, all‐cause post‐discharge death, and post‐discharge 
rehospitalization. Treatment effects were estimated using Cox proportional cause‐specific hazards 
models. Analyses were first performed using the original samples unadjusted and adjusted for 
characteristics associated with the outcome and other treatments (age, gender, history of HF, 
coronary artery disease, atrial fibrillation, diabetes, systolic blood pressure at admission, diastolic 
blood pressure, heart rate, renal function, hyperglycaemia, hyponatraemia) and secondly using the 
matching sample. Treatment effects were also estimated in different clinically relevant subgroups 
using Cox model with interaction between treatment and subgroup.  
 
Plots of Kaplan–Meier for time to long‐term all‐cause mortality in the whole cohort and 
propensity‐score matched cohorts, as well as in‐hospital mortality and post‐discharge mortality in 
the matched cohorts were performed. These plots were divided by treatment.  
 
All analyses were performed using SAS statistical software version 9.4 (SAS institute, Inc., 
Cary, NC, USA).  
Results 
A total of 6926 AHF patients were included in the study. Median duration of follow‐up was 
389.0 (366.0–491.0) days. Among hospitalized AHF patients, 1304 received a combination of i.v. 
vasodilators (mostly nitrates) and i.v. diuretics during the initial AHF management. They were 
compared to 4083 patients receiving i.v. diuretics alone. Furthermore, a separate analysis was 
performed with 833 patients who received one or more i.v. inotropes and/or vasopressors. They 
were compared to 6067 patients who received neither i.v. inotropes, nor vasopressors (Figure 1).  
  
 
 
 
Figure 1. Hospitalized acute heart failure (AHF) patients flowchart through the study of the European Society of 
Cardiology Heart Failure Long‐Term (ESC‐HF‐LT) registry. (A) Analysis of the combination of intravenous (IV) 
vasodilator and IV diuretics. (B) Analysis of IV inotrope and (or) vasopressor treatment. *This includes patients receiving 
oral diuretics and no vasodilators (n = 809); or no IV vasodilators and no diuretics (IV or oral) (n = 304).  
Combination of i.v. vasodilators and diuretics and outcome 
Table 1 shows baseline characteristics of patients who received the combination of i.v. 
vasodilator + i.v. diuretic and those receiving i.v. diuretics alone, before and after propensity score 
matching (n = 976 paired‐matched patients). Duration of i.v. administration of vasodilators was 
greater than 12 hours for 45% of AHF patients.  
Table 1. Baseline characteristics before and after propensity score matching for patients who received intravenous vasodilators and diuretics vs. those 
receiving intravenous diuretics alone 
Baseline 
characteristics 
Before propensity score matching  After propensity score matching 
Vasodilators + diuretics 
(n = 1304) 
 
Diuretics alone 
(n = 4083) 
 
Standardized 
difference 
 
Vasodilators + diuretics 
(n = 976) 
 
Diuretics alone 
(n = 976) 
 
Standardized 
difference 
n Stat  n Stat  (%)  n Stat  n Stat  (%) 
                
Age, years 1304 68.1 ± 12.0  4083 69.7 ± 13.2  12.8  976 68.9 ± 12.2  976 69.1 ± 12.7  1.7 
Female gender 1304 505 (38.7)  4083 1535 (37.6)  2.3  976 368 (37.7)  976 382 (39.1)  2.9 
BMI, kg/m2 1299 29.7 ± 5.3  4058 28.3 ± 5.5  25.1  976 29.0 ± 5.2  976 28.8 ± 5.4  4.2 
Primary diagnosis 1304 
 
 4083 
 
 
 
 976 
 
 976 
 
 
 
Ischaemic heart 
disease  
935 (71.7) 
 
 
2076 (50.8) 
 
43.8 
 
 
670 (68.6) 
 
 
705 (72.2) 
 
7.9 
Non‐ischaemic 
heart disease  
369 (28.3) 
 
 
2007 (49.2) 
 
43.8 
 
 
306 (31.4) 
 
 
271 (27.8) 
 
7.9 
Clinical presentation 1304 
 
 4082 
 
 
 
 976 
 
 975 
 
 
 
ACS/HF 
 
348 (26.7)  
 
348 (8.5)  49.1  
 
235 (24.1)  
 
260 (26.6)  5.9 
Cardiogenic shock 
 
24 (1.8)  
 
125 (3.1)  7.9  
 
24 (2.5)  
 
22 (2.3)  1.4 
Decompensated 
HF  
412 (31.6) 
 
 
2869 (70.3) 
 
83.9 
 
 
406 (41.6) 
 
 
375 (38.4) 
 
6.5 
Hypertensive HF 
 
114 (8.7)  
 
120 (2.9)  24.9  
 
67 (6.9)  
 
70 (7.2)  1.2 
Pulmonary oedema 
 
397 (30.4)  
 
443 (10.8)  49.9  
 
235 (24.1)  
 
231 (23.7)  1.0 
Right HF 
 
9 (0.7)  
 
177 (4.3)  23.4  
 
9 (0.9)  
 
17 (1.7)  7.2 
Previous atrial 
fibrillation 
1304 423 (32.4) 
 
4083 1980 (48.5) 
 
33.2 
 
976 354 (36.3) 
 
976 336 (34.4) 
 
3.9 
Cardiovascular co‐
morbidities   
 
  
 
 
 
  
 
  
 
 
Obesity 1299 566 (43.4)  4058 1277 (31.3)  25.3  976 356 (36.5)  976 347 (35.6)  1.9 
Diabetes 1304 595 (45.6)  4083 1587 (38.9)  13.7  976 429 (44.0)  976 441 (45.2)  2.5 
Hypertension 1304 953 (73.1)  4079 2563 (62.8)  22.0  976 665 (68.1)  972 687 (70.4)  4.9 
Peripheral vascular 
disease 
1304 190 (14.6) 
 
4080 580 (14.2) 
 
1.0 
 
976 156 (16.0) 
 
973 147 (15.1) 
 
2.5 
Non‐cardiovascular 
co‐morbidities   
 
  
 
 
 
  
 
  
 
 
COPD 1304 237 (18.2)  4081 828 (20.3)  5.3  976 191 (19.6)  975 204 (20.9)  3.3 
Chronic kidney 
disease 
1304 344 (26.4) 
 
4083 1213 (29.7) 
 
7.4 
 
976 249 (25.5) 
 
976 270 (27.7) 
 
4.9 
Sleep apnoea 1289 34 (2.6)  3987 116 (2.8)  1.4  965 32 (3.3)  956 19 (1.9)  8.3 
Liver dysfunction 1304 69 (5.3)  4082 398 (9.7)  17.0  976 58 (5.9)  975 73 (7.5)  6.1 
Depression 1303 100 (7.7)  4076 303 (7.4)  0.9  975 75 (7.7)  974 91 (9.3)  5.9 
Current malignant 
(cancer) disease 
1304 47 (3.6) 
 
4078 229 (5.6) 
 
9.6 
 
976 37 (3.8) 
 
971 32 (3.3) 
 
2.8 
Symptoms and signs 
  
 
  
 
 
 
  
 
  
 
 
Peripheral 
hypoperfusion/cold 
1300 274 (21.0) 
 
4061 728 (17.8) 
 
8.1 
 
972 215 (22.0) 
 
971 212 (21.7) 
 
0.7 
Peripheral oedema 1303 636 (48.8)  4078 2701 (66.2)  35.7  975 541 (55.4)  975 535 (54.8)  1.2 
JVP >6 1242 475 (36.4)  3840 1559 (38.2)  3.6  921 372 (38.1)  905 349 (35.8)  4.9 
Pulmonary rales 1300 1180 (90.5)  4068 3222 (78.9)  32.6  972 860 (88.1)  970 855 (87.6)  1.6 
NYHA functional 
class 
1303 
 
 
4075 
 
 
 
 
975 
 
 
975 
 
 
 
II 
 
87 (6.7)  
 
421 (10.3)  13.1  
 
82 (8.4)  
 
97 (9.9)  5.3 
III 
 
584 (44.8)  
 
2336 (57.2)  25.1  
 
464 (47.5)  
 
439 (45.0)  5.1 
IV 
 
632 (48.5)  
 
1318 (32.3)  33.4  
 
429 (44.0)  
 
439 (45.0)  2.1 
SBP, mmHg 1304 148.0 ± 33.1  4083 128.4 ± 26.0  65.8  976 139.2 ± 29.1  976 139.3 ± 30.2  0.3 
DBP, mmHg 1304 86.2 ± 18.2  4074 76.7 ± 14.6  57.5  976 82.0 ± 16.4  976 81.7 ± 16.1  1.4 
Heart rate, b.p.m. 1304 98.1 ± 25.3  4083 91.5 ± 25.3  26.3  976 95.7 ± 25.3  976 94.3 ± 25.9  5.1 
Serum 
concentrations   
 
  
 
 
 
  
 
  
 
 
Sodium, mmol/L 1204 138.1 ± 5.6  3817 137.6 ± 5.5  8.3  901 137.7 ± 5.5  893 137.6 ± 5.7  1.8 
Table 1. Baseline characteristics before and after propensity score matching for patients who received intravenous vasodilators and diuretics vs. those 
receiving intravenous diuretics alone 
Baseline 
characteristics 
Before propensity score matching  After propensity score matching 
Vasodilators + diuretics 
(n = 1304) 
 
Diuretics alone 
(n = 4083) 
 
Standardized 
difference 
 
Vasodilators + diuretics 
(n = 976) 
 
Diuretics alone 
(n = 976) 
 
Standardized 
difference 
n Stat  n Stat  (%)  n Stat  n Stat  (%) 
Potassium, 
mmol/L 
1201 4.3 ± 0.6 
 
3807 4.4 ± 0.7 
 
9.5 
 
898 4.3 ± 0.6 
 
896 4.4 ± 0.7 
 
4.5 
Creatinine, mg/dL 1281 1.5 ± 2.4  4030 1.5 ± 4.1  1.5  955 1.5 ± 2.7  954 1.7 ± 8.3  2.0 
Uric acid, mg/dL 783 7.3 ± 8.4  2149 7.8 ± 8.4  6.2  526 7.5 ± 10.1  508 7.6 ± 2.7  0.5 
Fasting glucose, 
mg/dL 
1155 152.2 ± 75.2 
 
3523 132.3 ± 64.5 
 
28.3 
 
850 144.9 ± 69.3 
 
830 145.7 ± 71.5 
 
1.1 
BNP, pg/mL 117 1628.1 ± 2510.7  436 1378.6 ± 1708.4  11.6  98 1669.3 ± 2603.7  95 1061.2 ± 1401.4  29.1 
LVEF, % 876 40.3 ± 13.4  2650 40.5 ± 15.4  1.0  620 39.6 ± 13.2  556 40.7 ± 15.4  7.9 
Beta‐blockers pre‐
admission 
1304 604 (46.3) 
 
4078 2199 (53.9) 
 
15.1 
 
976 495 (50.7) 
 
971 498 (51.0) 
 
0.6 
ACEi pre‐admission 1304 724 (55.5)  4078 1930 (47.3)  16.6  976 511 (52.4)  971 515 (52.8)  0.8 
Intravenous 
inotropes 
181 
 
 
546 
 
 
 
 
160 
 
 
140 
 
 
 
Dobutamine 
 
84 (6.4)  
 
231 (5.7)  3.3  
 
71 (7.3)  
 
62 (6.4)  3.7 
Dopamine 
 
54 (4.1)  
 
135 (3.3)  4.4  
 
50 (5.1)  
 
29 (3.0)  10.9 
Enoximone 
 
1 (0.1)  
 
1 (0.0)  2.3  
 
1 (0.1)  
 
0 (0.0)  4.5 
Epinephrine 
 
3 (0.2)  
 
7 (0.2)  1.3  
 
3 (0.3)  
 
3 (0.3)  0.0 
Levosimendan 
 
25 (1.9)  
 
59 (1.4)  3.7  
 
21 (2.2)  
 
21 (2.2)  0.0 
Norepinephrine 
 
3 (0.2)  
 
33 (0.8)  8.1  
 
3 (0.3)  
 
8 (0.8)  6.8 
Other 
 
11 (0.8)  
 
80 (2.0)  9.5  
 
11 (1.1)  
 
17 (1.7)  5.2 
Outcome 
  
 
  
 
 
 
  
 
  
 
 
In‐hospital death 1304 67 (5.1)  4083 254 (6.2)  4.7  976 59 (6.0)  976 58 (5.9)  0.4 
Long‐term 
mortality 
1243 299 (22.9) 
 
3787 1167 (28.6) 
 
13.0 
 
932 227 (23.3) 
 
916 247 (25.3) 
 
4.8 
                
 
Data are presented as mean ± standard deviation, or number (%). 
ACEi, angiotensin‐converting‐enzyme inhibitor; ACS, acute coronary syndrome; BMI, body mass index; BNP, B‐type natriuretic peptide; COPD, 
chronic obstructive pulmonary disease; DBP, diastolic blood pressure; HF, heart failure; JVP, jugular venous pressure; LVEF, left ventricular ejection 
fraction; NYHA, New York Heart Association; SBP, systolic blood pressure.  
 
 
When studying the primary endpoint, long‐term all‐cause mortality was lower in AHF patients 
receiving i.v. vasodilator + i.v. diuretic than those receiving i.v. diuretics alone in both the whole 
(22.9% vs. 28.6%) and the matched cohorts (23.3% vs. 25.3%) (Table 1). When using multivariate 
Cox regression analysis, the hazard ratio (HR) for the association between the use of i.v. 
vasodilator and diuretic and long‐term all‐cause mortality was not statistically significant [HR 
0.784, 95% confidence interval (CI) 0.569–1.032] (see Supplementary material online, Figure S3).  
 
Concerning the secondary endpoints, no association was seen neither in the whole nor in the 
matched cohort between the use of i.v. vasodilator and diuretic and all‐cause in‐hospital mortality, 
all‐cause post‐discharge death or post‐discharge readmission. Kaplan–Meier analysis confirmed 
those results (Figure 2). Long‐term cardiovascular mortality was not significantly different 
between the two treatment groups in the matched cohort (adjusted HR 0.823, 95% CI 0.607–
1.116).  
 
 
 
Figure 2. Risk of all‐cause death in acute heart failure patients receiving intravenous (IV) vasodilators and diuretics (A), or 
IV inotropes and/or vasopressors (B). Kaplan–Meier analysis for all‐cause mortality and the hazard ratios (HR) and 95% 
confidence intervals in the propensity‐score matched cohort for 1‐year and in‐hospital mortality in patients receiving IV 
vasodilators (A) and IV inotropes and/or vasopressors (B).  
  
Use of i.v. inotropes and/or vasopressors and outcome 
Table 2 shows baseline characteristics of patients who received i.v. inotropes and/or 
vasopressors (n = 833) or not (n = 6067), before and after propensity score matching (n = 606 
paired‐matched patients). Dobutamine was the most used agent (43%) followed by dopamine 
(25%) and levosimendan (13%). Median duration of i.v. inotrope and/or vasopressor use was 24.0 
(IQR 24.0–60.0) hours (Table 3).  
Table 2. Baseline characteristics before and after propensity score matching for patients who received intravenous 
inotropes and/or vasopressors vs. other treatments and no inotropes 
Baseline 
characteristics 
Before propensity score 
matchingInotropes/vasopressors 
 
After propensity score 
matchingInotropes/vasopressors 
Yes (n = 833)  No (n = 6067)  
Standardiz
ed 
difference 
 Yes (n = 606)  No (n = 606)  
Standardiz
ed 
difference 
n Stat  n Stat  (%)  n Stat  n Stat  (%) 
                
Age, years 
83
3 
67.2 ± 13.3 
 606
7 
69.2 ± 13.0 
 
15.7 
 60
6 
67.7 ± 13.3 
 60
6 
67.2 ± 13.0 
 
3.6 
Female gender 
83
3 
278 (33.4) 
 606
7 
2278 (37.5) 
 
8.7 
 60
6 
202 (33.3) 
 60
6 
212 (35.0) 
 
3.5 
BMI, kg/m2 
80
8 
27.7 ± 5.1 
 576
3 
28.6 ± 5.5 
 
17.0 
 60
6 
27.7 ± 5.0 
 60
6 
27.8 ± 5.1 
 
0.6 
Primary diagnosis 
83
2  
 602
4  
 
 
 60
6  
 60
6  
 
 
Ischaemic heart 
disease  
498 (59.8) 
 
 
3363 (55.4) 
 
8.8 
 
 
344 (56.8) 
 
 
349 (57.6) 
 
1.7 
Non‐ischaemic 
heart disease  
334 (40.1) 
 
 
2661 (43.9) 
 
7.6 
 
 
262 (43.2) 
 
 
257 (42.4) 
 
1.7 
Clinical 
presentation 
81
2  
 579
2  
 
 
 60
6  
 60
5  
 
 
ACS/HF 
 
107 (12.8)  
 
843 (13.9)  3.1  
 
94 (15.5)  
 
95 (15.7)  0.5 
Cardiogenic 
shock  
158 (19.0) 
 
 
37 (0.6) 
 
65.0 
 
 
23 (3.8) 
 
 
27 (4.5) 
 
3.3 
Decompensated 
HF  
395 (47.4) 
 
 
3641 (60.0) 
 
25.5 
 
 
355 (58.6) 
 
 
342 (56.4) 
 
4.3 
Hypertensive HF 
 
5 (0.6)  
 
314 (5.2)  27.6  
 
5 (0.8)  
 
12 (2.0)  9.8 
Pulmonary 
oedema  
124 (14.9) 
 
 
747 (12.3) 
 
7.5 
 
 
108 (17.8) 
 
 
113 (18.6) 
 
2.1 
Right HF 
 
23 (2.8)  
 
210 (3.5)  4.0  
 
21 (3.5)  
 
16 (2.6)  4.8 
Previous atrial 
fibrillation 
83
3 
386 (46.3) 
 606
7 
2622 (43.2) 
 
6.3 
 60
6 
298 (49.2) 
 60
6 
308 (50.8) 
 
3.3 
Cardiovascular co‐
morbidities   
 
  
 
 
 
  
 
  
 
 
Obesity 
80
8 
217 (26.1) 
 576
3 
1951 (32.2) 
 
13.4 
 60
6 
161 (26.6) 
 60
6 
160 (26.4) 
 
0.4 
Diabetes 
83
3 
318 (38.2) 
 606
7 
2360 (38.9) 
 
1.5 
 60
6 
229 (37.8) 
 60
6 
237 (39.1) 
 
2.7 
Hypertension 
83
2 
455 (54.6) 
 606
0 
3994 (65.8) 
 
23.1 
 60
6 
346 (57.1) 
 60
4 
334 (55.1) 
 
4.0 
Peripheral 
vascular disease 
81
2 
151 (18.1) 
 578
8 
768 (12.7) 
 
15.2 
 60
6 
114 (18.8) 
 60
5 
114 (18.8) 
 
0.0 
Non‐
cardiovascular co‐
morbidities 
  
 
  
 
 
 
  
 
  
 
 
COPD 
83
2 
184 (22.1) 
 606
3 
1147 (18.9) 
 
7.9 
 60
6 
140 (23.1) 
 60
4 
159 (26.2) 
 
7.3 
Chronic kidney 
disease 
83
3 
317 (38.1) 
 606
5 
1480 (24.4) 
 
29.8 
 60
6 
226 (37.3) 
 60
6 
232 (38.3) 
 
2.0 
Sleep apnoea 
79
5 
17 (2.0) 
 568
0 
175 (2.9) 
 
5.4 
 59
4 
14 (2.3) 
 59
3 
23 (3.8) 
 
8.6 
Liver 
dysfunction 
81
2 
127 (15.2) 
 579
2 
391 (6.4) 
 
28.6 
 60
6 
85 (14.0) 
 60
5 
74 (12.2) 
 
5.4 
Depression 
83
0 
112 (13.4) 
 606
0 
391 (6.4) 
 
23.6 
 60
5 
70 (11.6) 
 60
5 
78 (12.9) 
 
4.0 
Current 
malignant 
(cancer) disease 
83
0 
47 (5.6) 
 
606
2 
275 (4.5) 
 
5.1 
 
60
5 
35 (5.8) 
 
60
5 
42 (6.9) 
 
4.7 
Table 2. Baseline characteristics before and after propensity score matching for patients who received intravenous 
inotropes and/or vasopressors vs. other treatments and no inotropes 
Baseline 
characteristics 
Before propensity score 
matchingInotropes/vasopressors 
 
After propensity score 
matchingInotropes/vasopressors 
Yes (n = 833)  No (n = 6067)  
Standardiz
ed 
difference 
 Yes (n = 606)  No (n = 606)  
Standardiz
ed 
difference 
n Stat  n Stat  (%)  n Stat  n Stat  (%) 
Symptoms and 
signs   
 
  
 
 
 
  
 
  
 
 
Peripheral 
hypoperfusion/c
old 
80
9 
381 (45.7) 
 
576
4 
795 (13.1) 
 
76.7 
 
60
4 
233 (38.4) 
 
60
2 
249 (41.1) 
 
5.4 
Peripheral 
oedema 
81
2 
500 (60.0) 
 578
7 
3167 (52.2) 
 
18.8 
 60
6 
387 (63.9) 
 60
3 
382 (63.0) 
 
1.7 
JVP >6 
77
5 
422 (50.7) 
 544
1 
1772 (29.2) 
 
44.9 
 57
4 
297 (49.0) 
 56
8 
272 (44.9) 
 
8.3 
Pulmonary rales 
80
7 
663 (79.6) 
 577
3 
4187 (69.0) 
 
24.4 
 60
3 
491 (81.0) 
 60
2 
482 (79.5) 
 
3.7 
NYHA functional 
class 
81
0  
 576
7  
 
 
 60
4  
 60
4  
 
 
II 
 
34 (4.1)  
 
959 (15.8)  40.0  
 
32 (5.3)  
 
25 (4.1)  5.5 
III 
 
237 (28.5)  
 
3234 (53.3)  52.3  
 
215 (35.5)  
 
199 (32.8)  5.6 
IV 
 
539 (64.7)  
 
1574 (25.9)  84.5  
 
357 (58.9)  
 
380 (62.7)  7.8 
SBP, mmHg 
81
2 
112.1 ± 27.2 
 579
3 
135.4 ± 27.6 
 
85.1 
 60
6 
117.9 ± 26.6 
 60
6 
119.7 ± 23.4 
 
7.0 
DBP, mmHg 
80
4 
69.4 ± 15.9 
 578
9 
79.9 ± 15.3 
 
67.5 
 60
6 
72.3 ± 15.3 
 60
6 
73.4 ± 13.5 
 
7.5 
Heart rate, b.p.m. 
81
2 
95.5 ± 28.1 
 579
3 
90.7 ± 25.0 
 
18.0 
 60
6 
94.6 ± 27.9 
 60
6 
94.2 ± 29.0 
 
1.4 
Serum 
concentrations   
 
  
 
 
 
  
 
  
 
 
Sodium, mmol/L 
78
1 
135.7 ± 6.3 
 540
5 
138.2 ± 5.0 
 
45.0 
 60
6 
136.2 ± 6.0 
 60
6 
136.0 ± 5.6 
 
4.6 
Potassium, 
mmol/L 
77
9 
4.4 ± 0.8 
 539
4 
4.4 ± 0.6 
 
2.9 
 60
2 
4.3 ± 0.7 
 60
3 
4.4 ± 0.7 
 
11.2 
Creatinine, 
mg/dL 
80
4 
1.6 ± 0.8 
 570
4 
1.4 ± 3.6 
 
7.1 
 60
5 
1.5 ± 0.7 
 60
2 
1.5 ± 0.8 
 
6.7 
Uric acid, mg/dL 
44
3 
8.0 ± 2.7 
 315
8 
7.4 ± 8.1 
 
10.0 
 34
6 
7.9 ± 2.7 
 34
7 
9.2 ± 23.5 
 
7.5 
Fasting glucose, 
mg/dL 
69
2 
139.7 ± 73.6 
 501
9 
133.1 ± 64.9 
 
9.6 
 53
3 
133.7 ± 63.5 
 54
1 
134.1 ± 64.3 
 
0.5 
BNP, pg/mL 84 
2480.4 ± 291
7.7 
 
614 
1171.9 ± 159
0.5 
 
55.7 
 
73 
2544.0 ± 309
9.2 
 
80 
1683.9 ± 218
8.0 
 
32.1 
LVEF, % 
55
5 
34.8 ± 14.6 
 375
4 
40.8 ± 14.8 
 
41.2 
 42
1 
35.1 ± 14.7 
 42
4 
38.3 ± 15.4 
 
21.2 
Beta‐blockers pre‐
admission 
80
9 
441 (52.9) 
 579
0 
3206 (52.8) 
 
0.2 
 60
5 
346 (57.1) 
 60
6 
344 (56.8) 
 
0.7 
ACEi pre‐
admission 
80
9 
353 (42.4) 
 579
0 
3001 (49.5) 
 
14.3 
 60
5 
276 (45.5) 
 60
6 
268 (44.2) 
 
2.7 
Intravenous 
inotropes 
83
3  
 
0 
 
 
 
 60
6  
 
0 
 
 
 
Dobutamine 
 
354 (42.5)  
 
0 (0.0)  
 
 
 
256 (42.2)  
 
0 (0.0)  
 
Dopamine 
 
206 (24.7)  
 
0 (0.0)  
 
 
 
157 (25.9)  
 
0 (0.0)  
 
Enoximone 
 
2 (0.2)  
 
0 (0.0)  
 
 
 
2 (0.3)  
 
0 (0.0)  
 
Epinephrine 
 
14 (1.7)  
 
0 (0.0)  
 
 
 
8 (1.3)  
 
0 (0.0)  
 
Levosimendan 
 
109 (13.1)  
 
0 (0.0)  
 
 
 
84 (13.9)  
 
0 (0.0)  
 
Norepinephrine 
 
45 (5.4)  
 
0 (0.0)  
 
 
 
18 (3.0)  
 
0 (0.0)  
 
Other 
 
103 (12.4)  
 
0 (0.0)  
 
 
 
81 (13.4)  
 
0 (0.0)  
 
Table 2. Baseline characteristics before and after propensity score matching for patients who received intravenous 
inotropes and/or vasopressors vs. other treatments and no inotropes 
Baseline 
characteristics 
Before propensity score 
matchingInotropes/vasopressors 
 
After propensity score 
matchingInotropes/vasopressors 
Yes (n = 833)  No (n = 6067)  
Standardiz
ed 
difference 
 Yes (n = 606)  No (n = 606)  
Standardiz
ed 
difference 
n Stat  n Stat  (%)  n Stat  n Stat  (%) 
Outcome 
  
 
  
 
 
 
  
 
  
 
 
In‐hospital death 
83
2 
170 (20.4) 
 606
7 
214 (3.5) 
 
53.9 
 60
6 
92 (15.2) 
 60
6 
49 (8.1) 
 
22.3 
Long‐term 
mortality 
79
7 
364 (43.7) 
 568
4 
1410 (23.2) 
 
44.4 
 58
0 
241 (39.8) 
 56
2 
178 (29.4) 
 
22.0 
                
 
Data are presented as mean ± standard deviation, or number (%). 
ACEi, angiotensin‐converting‐enzyme inhibitor; ACS, acute coronary syndrome; BMI, body mass index; BNP, B‐type 
natriuretic peptide; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; HF, heart failure; JVP, 
jugular venous pressure; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; SBP, systolic 
blood pressure.  
Table 3. Duration and dosage of treatment with intravenous inotropes and/or vasopressors and their association with long‐
term all‐cause death 
Inotrope/vasopressor Dobutamine Dopamine Levosimendan Norepinephrine Epinephrine 
      
(whole cohort, n = 833) (n = 354) (n = 206) (n = 109) (n = 45) (n = 14) 
Hours of treatment 
     
Mean ± SD 42.5 ± 29.9 43.4 ± 32.3 24.8 ± 6.3 40.2 ± 28.3 37.6 ± 41.7 
Median (IQR) 36.0 (23.0–72.0) 
36.0 (20.0–
72.0) 
24.0 (24.0–24.0) 35.0 (17.0–60.0) 
22.0 (1.0–
72.0) 
Long‐term all‐cause death, % 37.9 49.0 38.5 55.6 64.3 
Inotrope/vasopressor Dobutamine Dopamine Levosimendan Norepinephrine Epinephrine 
(matched cohort, n = 606) (n = 512) (n = 314) (n = 168) (n = 36) (n = 16) 
HR (95% CI) for long‐term all‐
cause death 
1.055 (0.727–
1.531) 
1.628 (1.031–
2.572) 
1.229 (0.618–
2.445) 
3.762 (0.903–
15.663) 
NA 
      
 
Each of the 833 patients received at least one inotrope and/or vasopressor. Investigators indicated the main inotrope and/or 
vasopressor used in the initial management of acute heart failure. Of note, for 105 patients, investigators indicated inotropes 
and/or vasopressors other than those presented in the table.  
CI, confidence interval; HR, hazard ratio; IQR, interquartile range; NA, not available; SD, standard deviation.  
 
 
  
The primary endpoint of long‐term all‐cause mortality was greater in patients receiving i.v. 
inotrope and/or vasopressor compared to those who did not, whether analyses were performed in 
the whole (43.7% vs. 23.2%) or in the matched cohort (39.8% vs. 29.4%). Unadjusted and 
adjusted HR on the whole or matched cohort are shown in Figure 3. Using the multivariate Cox 
regression analysis, adjusted HR for the association between the use of i.v. inotrope and/or 
vasopressor and long‐term all‐cause mortality was 1.720 (95% CI 1.498–1.975] in the whole 
cohort and 1.434 (95% CI 1.128–1.823) in the matched cohort. Adjusted HR for long‐term all‐
cause mortality remained roughly between 1.5 and 2 in all clinically relevant subgroups of the 
matched cohort (see Supplementary materials online, Figure S4 and Table S1) with few positive 
interactions (age or peripheral hypoperfusion). 
 
 
 
Figure 3. Hazard ratio for the association between the use of inotropes/vasopressors and (A) long‐term all‐cause mortality, 
(B) in‐hospital mortality, (C) post‐discharge all‐cause mortality, (D) rehospitalization, (E) long‐term cardiovascular 
mortality. CI, confidence interval.  
Concerning the secondary endpoints, adjusted HR for associations between the use of i.v. 
inotrope and/or vasopressor and all‐cause in‐hospital mortality were 3.138 (95% CI 2.432–4.048) 
in the whole cohort and 1.873 (95% CI 1.151–3.048) in the matched cohort (Figure 3). Adjusted 
HR for all‐cause post‐discharge mortality were 1.249 (95% CI 1.059–1.474) in the whole cohort. 
However, this association became non‐significant after propensity score matching (HR 1.078, 95% 
CI 0.769–1.512 in the matched cohort). No association was found between the use of i.v. inotrope 
and/or vasopressor and all‐cause rehospitalization (HR 1.117, 95% CI 0.788–1.582 in the matched 
cohort). Adjusted HR for the association between i.v. inotrope and/or vasopressor use and long‐
term cardiovascular mortality was also significant in the whole as well as in the matched cohorts 
(HR 2.522, 95% CI 2.137–2.977, and HR 1.832, 95% CI 1.369–2.451, respectively).  
  
Sensitivity analysis (presented in the Supplemental Figure S5) confirmed the associations 
between the use of i.v. inotropes and/or vasopressors and long‐term all‐cause mortality throughout 
geographic regions (see also Supplementary material online, Table S2). Moreover, adjusted HR 
showed a significant association between dopamine and all‐cause long‐term mortality (HR 1.628, 
95% CI 1.031–2.572) but not with dobutamine or levosimendan (HR 1.055, 95% CI 0.727–1.531, 
and HR 1.229, 95% CI 0.618–2.445, respectively). This detrimental association of dopamine with 
long‐term mortality is mostly seen in AHF patients with systolic blood pressure < 130 mmHg and 
signs of peripheral hypoperfusion (HR 3.34, 95% CI 1.01–11.11) rather than in patients with 
systolic blood pressure ≥ 130 mmHg and no clinical signs of hypoperfusion (HR 0.33, 95% CI 
0.03–3.32).  
Discussion 
This study describes the contemporary use of i.v. vasoactive medications and their association 
with long‐term survival in an unselected global patient population with AHF. Our results showed 
that the use of vasodilators and diuretics in the initial management of AHF did not alter long‐term 
clinical outcomes. Notably, this is the first analysis to demonstrate that the use of inotropes and/or 
vasopressors in AHF was associated with increased long‐term risk of all‐cause and cardiovascular 
death throughout different geographic regions.  
 
The ESC‐HF‐LT registry indicated that only a minority of AHF patients received vasodilators 
during the initial hospital management. The combination of vasodilators and diuretics had a 
tendency to lower the risk of mortality compared to diuretics alone. However, statistical 
significance is diminished due to the smaller sample size. As a result, our study showed neither 
harmful, nor beneficial associations with clinical outcomes. These findings are consistent with the 
neutral effect of vasodilators on mortality described in previous studies,12, 13 in particular a post‐
hoc analysis of ESCAPE trial,14 as well as novel agents such as nesiritide in ASCEND‐HF15 and 
ularitide in TRUE‐AHF.16, 17 
 
Our study further showed that the prevalence of the use of inotropes and/or vasopressors in the 
ESC‐HF‐LT registry was still common (12%), though lower than in previous studies: the Italian 
IN‐HF Outcome registry (20%, n = 360)18 and the global ALARM‐HF registry (33%, n = 1617).8 
Our study also suggests a rather inappropriate use of inotropes and/or vasopressors, as only a small 
proportion of patients treated with catecholamines presented with cardiogenic shock and less than 
half had signs of peripheral hypoperfusion. Despite the widespread use of inotropes, data from 
controlled trials have failed to demonstrate benefit with these agents.4, 7-9, 19 On the contrary, 
catecholamines have been associated with increased risk for adverse outcomes. The CardShock 
study recently demonstrated the association between the use of adrenaline in cardiogenic shock 
and a striking myocardial injury as well as increased 90‐day mortality, thus raising questions about 
the safety of this treatment.20 The increasing safety concerns for the use of catecholamines are 
reflected in current clinical practice guidelines. The recent ESC guidelines for the diagnosis and 
treatment of acute and chronic HF further restrict the use of inotropic agents to AHF patients only 
with symptomatic hypotension and hypoperfusion.21, 22 Our results confirm that the use of 
inotropes and/or vasopressors in AHF was consistently associated with short‐term death, in line 
with previous studies, including the global ALARM‐HF registry.8 Our study further extended 
these findings by showing that detrimental effects of inotropes and/or vasopressors on long‐term 
all‐cause and cardiovascular mortality were still pronounced several months after AHF episodes 
and seen in all studied geographic regions. Our study, however, showed the lack of association 
between inotropes and/or vasopressors and long‐term mortality in hospital survivors. This may 
suggest an immediate rather than prolonged detrimental effect of inotropes and/or vasopressors on 
clinical outcome. This needs further evaluation.  
  
The present study also indicates that dopamine has an excess mortality compared to other 
studied inotropes (such as dobutamine and levosimendan). However, our study was not adequately 
powered to analyse the differences between individual inotropes and/or vasopressors, thus this 
finding remains to be confirmed in future studies.  
 
Our study has important clinical implications as it reinforces safety concerns of inotropes 
and/or vasopressors in AHF. Our results suggest that the recommendation of careful use of i.v. 
catecholamines in AHF seems wise. Furthermore, it highlights the universal need for safe agents to 
stabilize and restore haemodynamics in AHF patients. What is more, our study draws attention to 
the use of dopamine, as it was associated with worse short‐ and long‐term outcomes compared to 
other inotropes and/or vasopressors.  
Limitations 
Our study has several limitations. The observational design of our study is subject to selection 
bias and confounding. Propensity score methodology allowed balancing groups according to 
variables that were recorded in the ESC‐HF‐LT registry. This is an especially detailed registry 
notably with regard to AHF related variables. By matching patients by propensity scores generated 
from 25 baseline variables, we accounted for most conceivable confounders. Nevertheless, we 
cannot rule out inaccuracies in registry data or residual unmeasured confounding. Propensity score 
analysis strengthens our findings but still cannot replace a randomized study design. Since this was 
a multicentre registry, it should not be overlooked that some centres recorded data differently than 
others. There was no central committee for the establishment of AHF diagnosis, or to assure that 
the requirements of enrolment were equally respected in all countries. However, centres and 
countries were accounted for in the propensity score development. Furthermore, the associations 
were strong and consistent among the different analyses conducted (unadjusted, adjusted and 
propensity scoring). Thus, the impact of any one particular centre should be limited in most cases. 
There is also a certain amount of missing data that may have influenced the results, especially 
concerning certain markers that reflect disease severity (such as B‐type natriuretic peptide and left 
ventricular ejection fraction). It should also be noted that propensity score does not allow to match 
patients who have an absolute indication for the use of vasoactive medications, such as 
cardiogenic shock. The number of patients presenting with cardiogenic shock was small and 
therefore not sufficient to analyse the impact of vasopressors and inotropes in this subgroup of 
patients. However, the detrimental association with the use of inotropes and/or vasopressors and 
mortality remained evident in the subgroup analysis of hypotensive patients as well as patients 
with a low ejection fraction. Another important limitation of our study is the lack of data on doses 
of different inotropes. This might be the source of bias as there might be disparities between low 
and high dose of certain catecholamines, such as dopamine. It should also be noted that there is a 
difference between levosimendan and other inotropes, because levosimendan can be administered 
with much less monitoring and does not require an intensive care unit setting. Therefore, this is a 
potential source of bias. Moreover, the study is also limited by the absence of data on the course of 
the disease during the first 24 hours of i.v. therapy administration. Post‐baseline factors such as 
clinical worsening during the admission could affect outcomes, and further analyses adjusting for 
markers of clinical worsening could have strengthened the propensity score analysis.  
  
Conclusions 
Our study, based on the ESC‐HF‐LT registry data, did not confirm any harms or benefits of the 
use of vasodilators on long‐term clinical outcomes. More importantly, observable associations 
were revealed between the use of inotropes and/or vasopressors and long‐term all‐cause and 
cardiovascular death in all geographic regions. We also observed that dopamine had the greatest 
negative association with mortality among studied inotropes. Because our study does not prove 
causality, these findings need to be confirmed in the setting of a prospective randomized clinical 
trial.  
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